Ascendiant Capital initiated coverage on Daxor with a new price target
$DXR
Medical/Dental Instruments
Health Care
Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00
Save time and jump to the most important pieces.
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4/A - DAXOR CORP (0000027367) (Issuer)
N-CEN - DAXOR CORP (0000027367) (Filer)
N-CSR - DAXOR CORP (0000027367) (Filer)
N-PX - DAXOR CORP (0000027367) (Filer)
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management's presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in advance via email to: [email protected]. To participate, register HERE. A webcast replay of the call will be available on the Company's website at Daxor.com. About Daxor Corporation Daxor Corporatio
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw." — Anonymous As we forge ahead into this pivotal year, Daxor remains laser-focused on our mission, unwavering in our execution of strategic goals, and fueled by the relentless determination for transformative growth and adoption of our technology. 2024 was remarkable for the
Ascendiant Capital initiated coverage of Daxor with a rating of Buy and set a new price target of $21.00
Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration between the Company and healthcare professionals. He will be a key advisor, offering insights to inform corporate development strategies and advance the organization's growth objectives. Michael Fe
Oak Ridge, TN, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the appointment of Linda Cooper as Vice President of Project Management. "Linda joins Daxor with over 30 years of experience in product development and commercialization in the medical device industry. Linda's proven track record makes her an excellent addition to the Daxor team to lead our development projects including our next generation systems, as well as overseeing our operations at our Oak Ridge facility," said Michael Feldschuh, CEO and President of Daxor Corporation. Before joining Daxor, Linda has held several senior leadersh
Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor Corporation, the global leader in blood volume measurement technology, today announces significant new findings from Duke University Medical Center published in the prestigious American Heart Journal. The research demonstrates how Blood Volume Analysis (BVA) enables precise measurement of red blood cell mass (RBCM) and effectively differentiates between true and dilutional anemia in heart failure (HF) patients. The detection of true anemia and its management is a key part of Heart Failur
Gold-Standard Technology Now Available in East Tennessee and Pacific Northwest Through Strategic Dual-Model Implementation Oak Ridge, TN, May 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor Corporation, the global leader in blood volume measurement technology, announces the expansion of its innovative diagnostic solutions into two additional U.S. healthcare systems, further advancing the standard of care for cardiovascular and critical care patients nationwide. Daxor continues to drive healthcare transformation through its dual implementation models, tailored to meet the unique needs of diverse clinical settings. This strategic expansion includes: A premier regional r
Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the opening of a new BVA program at a premier Florida healthcare center in the Tampa Bay region. This expansion integrates Daxor's innovative blood volume analysis (BVA) testing across the facility's inpatient and outpatient care programs, revolutionizing fluid management precision and enhancing treatment outcomes for a spectrum of conditions. The facility will utilize Daxor's state-of-the-art Tennessee-based CLIA-certified ezBVA Lab that delivers comprehensive b
4 - DAXOR CORP (0000027367) (Issuer)
4 - DAXOR CORP (0000027367) (Issuer)
4/A - DAXOR CORP (0000027367) (Issuer)